Identification of novel CYP2A6 inhibitors by virtual screening

Minna K. Rahnasto, Hannu A. Raunio, Carsten Wittekindt, Kaisa A. Salminen, Jukka Leppänen, Risto O. Juvonen, Antti Poso, Maija K. Lahtela-Kakkonen

Index: Bioorg. Med. Chem. 19 , 7186-93, (2011)

Full Text: HTML

Abstract

The human CYP2A6 enzyme metabolises several xenobiotics including nicotine, the addictive component in tobacco. Reduced activity of CYP2A6, either for genetic reasons or by administering inhibitors of CYP2A6, reduces tobacco smoking. The aim was to design novel inhibitors of CYP2A6 using 3D-QSAR analysis combined with virtual screening. A 3D-QSAR model was utilised to identify the most important features of the inhibitors, and this knowledge was used to design inhibitors for CYP2A6. Chemical database screening yielded several potent inhibitor candidates such as alkylamine derivatives (compound no. 5, IC(50)=0.1 μM) and 1-benzothiophene-3-carbaldehyde that can be used as lead compounds in the development of drugs for smoking reduction therapy.Copyright © 2011 Elsevier Ltd. All rights reserved.